NorthWest Biotherapeutics Inc (NWBO)

[GermanCol]

If we compare the results with the latest data that you mention, the conclusion of my post doesn´t change:

And the reason for this is actually good news because this can be explained as follows. At the beginning, the treatment arm started to do better because of DCVaxL, then as progression and pseudo progression (confounding factor) started, patients were taken out of the treatment arm and of the “placebo arm” to start going into the recurrent GBM treatment arm. So the already dead patients started to have higher effect in the treatment arm because there were less patients at risk. Also, important to take into account when analyzing this effect that recurrent GBM treatment arm is measured from recurrence, not from randomization or surgery. Then, after that, with the long term positive effect of DCVax, which is higher for patients that started earlier with the treatment, the treatment arm patients continued doing better and not only counteracted the effect mentioned of having less at risk (that is just a mathematical effect), but also continued doing better and better than what was shown in the interim blended blinded results.

And again, for 46.5 months,16.5 % from the final results is better than 15% from the interim, that is the last available information we have for that time.

Now, about this that you mention:

I will accept your 26% read of the NYAS K/M over my 25% (old man eyes here). But that still leaves the 99 patient arm at 33.3% [28.2+2.2*232/99]. That is a decent improvement over 26%.

I have a whole post with an analysis for the 35 patients that never crossed over and for the 64 that were in the rGBM arm in detail (that adds up your 99), that together with the post you are replying to explains what is happening and demonstrates that what you are saying is not true.

Here is the link:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168899638